Fastest Drug Developers Outperform Peers
Drugs developed by the fastest companies each gained an average of $1.1 billion in incremental prescription revenue and saved an average of $30 million in out-of-pocket development costs, compared to those of the slowest companies, according to Tufts University's Center for the Study of Drug Development (CSDD).
Drugs developed by the fastest companies each gained an average of $1.1 billion in incremental prescription revenue and saved an average of $30 million in out-of-pocket development costs, compared to those of the slowest companies, according to Tufts University’s Center for the Study of Drug Development (CSDD). The study was published in the center’s September/October Impact Report.
“Speed demon companies-those that perform consistently better across a number of dimensions, earn higher revenues and have lower development costs-implement efficient practices across their portfolios,” said Ken Getz, senior research fellows at CSDD, and coauthor of the study.
“The study shows that “speed is not a chance event,” according to Getz. “Speedy companies implement activities that have a dramatic impact on development cycles.”
Between 2000 and 2005, the fastest drug development companies were Bayer, Astra-Zeneca, Allergan, Boehringer Ingelheim, and Merck, according to CSDD. Each shortened its development and regulatory cycles by as much as 17 months, compared to average performing drug developers.
The Tufts study also found that:
- As a group, the fastest third of companies reduced their median development speed by 20% (from 66.5 months in 1994–1999 to 53 months in 2000–2005) and held regulatory cycle times flat at approximately 13 months in the 2000–20005 period.
- “Speed-demon” companies beat the median overall cycle time more than 83% of the time, in each therapeutic area where they compete.
- The fastest companies terminate 56% of discontinued projects in phase 1 clinical development vs. 36% for slowest companies.
According to Getz, although the strategies of the fast drug developers vary, all of the companies:
- Optimize resources
- Make maximum use of CROs
- Kill projects sooner, rather than ignore unfixable problems
- Commit to doing a better job
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
